Abstract
In the tumor-bearing host, T cells invariably fail to induce a clinically significant antitumor immune response. Although model systems support the existence of tumor peptide antigens, the molecular interactions critical for antigen presentation by the tumor cell remain unresolved. Here, we demonstrate that human follicular lymphoma cells are highly inefficient at presenting alloantigen despite their strong expression of major histocompatibility complex and low-to-intermediate expression of some adhesion and B7 costimulatory molecules. Activation of follicular lymphoma cells via CD40 induces or up-regulates both adhesion and B7 costimulatory molecules essential to repair this defect. More importantly, once primed, alloreactive T cells efficiently recognize unstimulated follicular lymphoma cells. Thus, correction of defective tumor immunity requires not only expression of major histocompatibility complex but also sufficient expression of multiple adhesion and costimulatory molecules.
MeSH Terms
Antigen-Antibody Reactions
Antigen-Presenting Cells/immunology
Antigens, CD/immunology
Antigens, Differentiation, B-Lymphocyte/immunology
CD40 Antigens
Cell Adhesion/immunology
Cells, Cultured
Humans
Isoantigens/biosynthesis
Lymphocyte Activation
Lymphoma, Follicular/immunology
T-Lymphocytes/immunology
Tumor Cells, Cultured
Up-Regulation
Chemicals
Antigens, CD
Antigens, Differentiation, B-Lymphocyte
CD40 Antigens
Isoantigens
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Schultze J L
Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Cardoso A A
Freeman G J
Seamon M J
Daley J
Pinkus G S
Gribben J G
Nadler L M
References (28)
28 references, click to expand
-
Role of B7-1 in mediating an immune response to myeloid leukemia cells.
Blood. 1995 May 1;85(9):2507-15
PMID: 7537118
-
CD40 ligand triggered interleukin-6 secretion in multiple myeloma.
Blood. 1995 Apr 1;85(7):1903-12
PMID: 7535594
-
Gene transfer as cancer therapy.
Adv Immunol. 1995;58:417-54
PMID: 7741031
-
The normal and malignant germinal centre.
Clin Haematol. 1982 Oct;11(3):531-59
PMID: 6756733
-
Expression of B cell activation antigens on normal and malignant B cells.
Leukemia. 1987 Jan;1(1):9-15
PMID: 3118102
-
Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1).
Cell. 1987 Dec 4;51(5):813-9
PMID: 3315233
-
The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells.
J Immunol. 1990 Jun 15;144(12):4579-86
PMID: 1972160
-
Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation.
J Exp Med. 1991 Mar 1;173(3):721-30
PMID: 1847722
-
Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma.
N Engl J Med. 1991 Nov 28;325(22):1525-33
PMID: 1944436
-
Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4.
Cell. 1992 Dec 24;71(7):1093-102
PMID: 1335364
-
Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells.
Science. 1993 Jan 15;259(5093):368-70
PMID: 7678351
-
Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal.
J Exp Med. 1993 Apr 1;177(4):925-35
PMID: 7681471
-
Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma.
Nature. 1993 Apr 22;362(6422):755-8
PMID: 8469286
-
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.
Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3539-43
PMID: 8097319
-
Cancer vaccines.
Immunol Today. 1993 Jun;14(6):310-6
PMID: 8397772
-
B7 but not intercellular adhesion molecule-1 costimulation prevents the induction of human alloantigen-specific tolerance.
J Exp Med. 1993 Nov 1;178(5):1753-63
PMID: 7901318
-
Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation.
Science. 1993 Nov 5;262(5135):909-11
PMID: 7694363
-
New strategies for enhancing the immunogenicity of tumors.
Curr Opin Immunol. 1993 Oct;5(5):719-25
PMID: 7694593
-
Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation.
Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11059-63
PMID: 7504293
-
Costimulation of T cells for tumor immunity.
Immunol Today. 1993 Oct;14(10):483-6
PMID: 7506034
-
Naive versus memory CD4 T cell response to antigen. Memory cells are less dependent on accessory cell costimulation and can respond to many antigen-presenting cell types including resting B cells.
J Immunol. 1994 Mar 15;152(6):2675-85
PMID: 7908301
-
Tumour antigens. A new look for the 1990s.
Nature. 1994 Jun 2;369(6479):357
PMID: 8018207
-
Tumor antigens recognized by T lymphocytes.
Annu Rev Immunol. 1994;12:337-65
PMID: 8011285
-
The CD40 antigen and its ligand.
Annu Rev Immunol. 1994;12:881-922
PMID: 7516669
-
CD2 is involved in maintenance and reversal of human alloantigen-specific clonal anergy.
J Exp Med. 1994 Nov 1;180(5):1665-73
PMID: 7525835
-
Tumor immunotherapy: the tumor cell as an antigen-presenting cell.
Curr Opin Immunol. 1994 Oct;6(5):722-7
PMID: 7826527
-
MHC class II restricted tumor antigens and the role of CD4+ T cells in cancer immunotherapy.
Curr Opin Immunol. 1994 Oct;6(5):741-5
PMID: 7826529
-
Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice.
J Exp Med. 1995 Feb 1;181(2):619-29
PMID: 7836917